<DOC>
	<DOCNO>NCT00501332</DOCNO>
	<brief_summary>This investigation safety efficacy Maxy-G34 breast cancer patient treat TAC chemotherapy . Maxy-G34 give single injection cycle chemotherapy , plan total six chemotherapy cycle .</brief_summary>
	<brief_title>Evaluation Maxy-G34 Breast Cancer Patients Treated With TAC ( Docetaxel , Adriamycin , Cyclophosphamide ) Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Key 1 . Males female least 18 year age 2 . Diagnosis highrisk stage I , II IIIa breast cancer suitable adjuvant TAC chemotherapy base investigator judgment 3 . Candidates TAC chemotherapy , prior treatment anthracyclines Key 1 . Received chemotherapy within last 3 month prior screening , expect receive chemotherapy TAC / immunotherapy screen 30 day last planned study drug administration 2 . Any clinically significant finding history examination , opinion investigator , would preclude administration TAC chemotherapy full dose , include abnormal liver function , inadequate cardiac function clinically significant cardiac disease , neuropathy disease 3 . Prior bone marrow peripheral blood hematopoietic stem cell transplant 4 . Any active cancer history prior malignancy within last 5 year except carcinoma situ cervix , basal cell carcinoma squamous cell carcinoma skin surgically cure malignancy diagnose 5 year diagnosis breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>